Update on Biosimilars: The Canadian and Global Landscape (Complimentary from OHA)
As some of the most technologically-advanced and innovative treatment options, biologics and biosimilars are at the forefront of medicine today.
With an increasing number of biosimilars entering health care systems in Canada and around the world each year, physicians and other health care professionals, like nurses and hospital executives, will need to have a firm understanding of these medicines to help patients and caregivers make informed treatment choices.
Michael Reilly, Esq., Executive Director of the Alliance for Safe Biologics (ASBM) and Leigh Revers, PhD, Professor and Associate Director of the Master of Biotechnology Program at the University of Toronto, will participate in a moderated discussion led by Kim Furlong, Director at Amgen Canada. The discussion will focus on the biosimilars landscape in Canada and around the world, as well as cover notable developments over the past year. The session will include a brief overview of originator biologic drugs and biosimilars and how they differ. It will also touch on key considerations associated with biosimilars including: naming, automatic substitution, interchangeability and patient choice, among others.